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ABSTRACT 
Importance: There is limited information about the durability of glycemic control when 
different oral glucose-lowering therapies (GLTs) are used as add-on treatments to metformin 
(MET) in patients with type 2 diabetes mellitus (T2DM). 
Objective: To compare time to treatment failure between different classes of oral GLT when 
used as second line (add-on) treatments to MET monotherapy at HbA1c ≥ 7.5%. 
Design, setting and participants:  A retrospective cohort study on 20,070 patients who were 
newly treated with a sulphonylurea (SU), dipeptidyl-peptidase-4 (DPP-4) inhibitor or 
thiazolidinedione (TZD) following MET therapy failure (2007-2014).  Patients’ data was 
sourced from UK General Practices via The Health Improvement Network (THIN) database. 
The risk of dual therapy failure was compared between 3 treatment groups: MET+SU 
(reference group, n=15,508), MET+DPP-4 inhibitor (n=3,080) and MET+TZD (n=1,482). 
Follow-up was until treatment substitution or intensification with a 3rd GLT, or for up to 5 
years (totalling 46,430 person-years). Propensity score weighting and Cox proportional 
hazard regression analyses were employed. 
Main outcomes and measures: Risk of dual therapy failure was compared between 
treatment groups while adjusting for baseline covariates.  
Results: Unadjusted survival analysis showed the incidence of dual therapy failure at 1 year 
was 15% with SU, 23% with DPP-4 inhibitor and 8% with TZD.  Corresponding failure rates 
at 2 years were 26%, 38% and 12% respectively.  Adjusted multivariate models showed that, 
compared to the SU group, adding a DPP-4 inhibitor was associated with an increased risk of 
treatment failure (adjusted hazard ratio, aHR, 1.58; 95% CI: 1.48-1.68), while adding a TZD 
was associated with a reduced hazard (aHR, 0.45; 95% CI: 0.41-0.50).  Baseline parameters 
associated with an increased hazard of intensification included HbA1c, diabetes duration, 
gender, smoking status and the use of statins.  
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Conclusions and relevance: In routine clinical practice, adding a DPP-4 inhibitor to MET is 
associated with an increased, earlier requirement for treatment intensification compared to 
adding an SU or TZD.  Adding a TZD to MET resulted in the most durable glycemic 
response.  
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Introduction 
There is evidence that tight glucose control, especially in the early years after diagnosis, 
reduces the risk of long-term cardiovascular (CV) complications in patients with type 2 
diabetes mellitus (T2DM).1,2 International guidelines therefore recommend an 
individualized treatment strategy to achieve and maintain target levels of glycemic control.3  
Metformin (MET) is the usual first-line therapy when diet and exercise are insufficient, but 
due to the progressive decline in beta cell function many patients fail to maintain adequate 
levels of glycated hemoglobin (HbA1c) with monotherapy and require treatment 
intensification by adding a second oral agent.3,4  
 
For most patients in whom MET alone is no longer sufficient, the options include adding a 
sulphonylurea (SU), a dipeptidyl-peptidase-4 (DPP-4) inhibitor or a thiazolidinedione (TZD).  
While these drugs have shown broadly similar reductions in HbA1c in randomized trials, the 
durability of glycemic responses when added as dual therapy with MET in everyday practice 
is unknown.  Recent  observational studies,5,6 and randomized controlled trials,7 have mainly 
reported on the durability of glucose lowering therapies (GLTs) when used as initial 
monotherapy rather than as add-on treatments in patients with longer duration T2DM.  
  
Thus, the aim of this study was to compare the time to treatment failure among patients who 
added a DPP-4 inhibitor, SU or TZD to MET monotherapy in routine clinical practice, and to 
assess the glycemic and body weight responses over time.  
 
Methods 
Study design and data source 
We conducted retrospective cohort analyses of data from The Health Improvement Network 
(THIN) database, which contains anonymous patient data from more than 400 General 
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Practices throughout England and Wales.  THIN has been used previously to evaluate 
diabetes-related outcomes in routine clinical practice.8 
Study population 
The study population comprised a cohort of patients identified to have T2DM and registered 
to a practice for more than 12 months before the index date (January 1st 2007 - May 30th 
2014). The cohort included patients ≥ 18 years old who were newly treated with an SU, DPP-
4 inhibitor or TZD following MET therapy failure. Patients who were administered other 
GLTs such as glucagon-like peptide 1 receptor (GLP-1) agonists, sodium glucose co-
transporter 2 (SGLT2) inhibitors, glinides and acarbose were excluded from the study due to 
the small numbers of user cases. Also excluded were patients who added insulin treatment to 
MET monotherapy in order to enable us to compare different oral GLTs.  Standardized 
computerized routines were used to identify and extract information on patients’ prescriptions 
for GLTs using British National Formulary (BNF) codes, and patients’ diagnosis of disease 
conditions using Read codes.   
Exposure 
The exposures were incident intensification prescription of any SU (gliclazide, glimepiride, 
glipizide, glibenclamide or tolbutamide), a DPP-4 inhibitor (sitagliptin, vildagliptin, 
saxagliptin or linagliptin), or TZD (pioglitazone) as 2nd line GLT following MET 
monotherapy failure. Pioglitazone constitute 100% of TZDs in the data. The follow-up period 
commenced from the index date (the date of incident intensification prescription) through to 
the date of a censoring addition or substitution of another GLT at HbA1c ≥ 7.5%, up to 5 
years after the index date.  The study end date was May 30th 2014. Patients were segregated 
into three treatment groups based on the GLTs they received at baseline: MET + SU 
(reference/control group) vs. MET + DPP-4 inhibitor or MET + TZD.  
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Outcome 
The primary composite outcome was time to dual therapy failure.  This was defined as time 
to substitution or intensification of treatment with a 3rd agent at HbA1c ≥ 7.5%.  Secondary 
outcomes included the glycemic effectiveness and body weight responses. The risks of 
treatment failure in the study population were compared across the three treatment groups.  
Covariates  
Covariates were selected a priori on the basis of clinical significance. These are baseline 
demographic and medical parameters, and include: age, gender, social deprivation (measured 
using Townsend’s index scores), body weight, body mass index (BMI), baseline HbA1c, total 
cholesterol levels, low-density lipoprotein (LDL), high-density lipoprotein (HDL), 
triglycerides, systolic and diastolic BP, smoking status, duration of T2DM, glomerular 
filtration rate (GFR), serum albumin levels and urinary albumin-creatinine ratio (ACR). 
Others included the use of lipid-lowering drugs (mainly statins), antihypertensive drugs, 
aspirin and the following comorbidities at baseline: coronary heart diseases (CHD), 
peripheral arterial disease (PAD), hypoglycemia and heart failure.  
Statistical analyses 
Primary analyses include descriptive statistical analysis using Chi squared tests and logistic 
regression to assess all variables. We estimated a multinomial propensity score based on all 
the baseline covariates in our study.9 This was designed to estimate the probability that a 
patient’s initial 2nd line therapy was an SU (MET+SU was the treatment group with the 
largest number of patients).10  Propensity score (PS) was estimated via inverse-probability-
weighted regression adjustments (IPWRA)11 using a logistic regression model in which the 
treatment status (indicator variable) was regressed on the baseline covariates.12  
Balance in baseline covariates was assessed between the treatment groups by estimating the 
absolute standardized differences before and after propensity score weighting. A standardized 
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effect size ≥ 10% indicated serious imbalance.13 The variations in mean and frequency 
distribution of measured baseline covariates between treatment groups with the same 
estimated propensity score was summarized.  
Crude and adjusted Kaplan–Meier estimates of survival functions were calculated to evaluate 
the association of the treatment groups, and differences in survival were assessed via the log 
rank tests.  From the survival curves, we computed the probability of dual therapy failure 
occurring within a 5-year follow-up. We constructed Cox proportional hazards models 
adjusting for all covariates while including propensity score as a prognostic covariate. The 
marginal hazard ratios were estimated to enable us to quantify the adjusted risk of requiring 
intensification with a 3rd line glucose lowering agent in DPP-4 inhibitor or TZD treated 
groups compared to the SU group.  
We tested for violations of the proportional hazards assumptions using Schoenfeld residuals 
test.14 Point estimates with 95% confidence intervals (CI) at the conventional statistical 
significance level of 0.05 were used in the regression models. Missing data among covariates 
was accounted for with multiple imputations using the chained equation (MICE) model.15  
All analyses were conducted using R16 and Stata Software, version 13.17  
Sensitivity Analyses 
Additional sensitivity analyses were carried out to evaluate the robustness of our results by 
examining the assumption of no unmeasured confounding variable.18,19 Assumption was 
made for an unmeasured covariate that would influence the measure of effect.12  In addition, 
sensitivity analysis was carried out to compare results of covariates with missing data with 
those having multiple-imputed data to assess the reliability of the outcomes and the impact of 
missing data. 
Biases 
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Our analysis employed the “new user” design to minimize biases associated with prevalent 
use of intensification regimens.18  In an approach similar to that used in as-treated analyses, 
we used the intensification regimen to define drug exposure; post index date exposure to any 
GLT other than SU, DPP-4 inhibitor or TZD was not permitted in our study to reduce 
confounding by indication.  In addition, to eliminate bias that may occur from Kaplan–Meier 
estimates of survival functions due to an unbalanced distribution of covariates, we used the 
adjusted log-rank test to compare the equality of the survival curves in the propensity score 
weighted cohort.20  
 
Results 
General patient characteristics  
After screening 23,090 patients who intensified MET treatment with a 2nd line therapy, 
20,070 patients made the criteria for cohort entry and were assigned to one of three treatment 
groups as outlined in the Supplement eFigure 1. The number (proportion) of patients assigned 
to each treatment group included 15,508 (77%) who added a SU therapy (median follow-up 
2.1 yrs, IQR: 0.8-4.0 yrs), 3,080 (15%) added a DPP-4 inhibitor (median follow-up 1.3 yrs, 
IQR: 0.5-2.4 yrs), and 1,482 (7%) added a TZD (median follow-up 3.7 yrs, IQR: 1.8-4.9 yrs). 
Their corresponding median time before treatment failure was 1.7, 0.9 and 2.6 yrs, 
respectively.  
Overall, patients had a mean age of 59 yrs and were predominantly male (59%). Compared 
with patients who added other GLTs, those who added an SU appeared to be older (60 vs 57 
yrs), had higher mean HbA1c levels (9.1% vs 8.6%), lower BMI and lower diabetes duration 
(Table 1).  The patients’ socioeconomic status was similar across the treatment groups. 
Before PS weighting, many of the measured covariates had a standardized difference above 
the 0.10 level (Table 1). However, the application of PS weighting brought into balance the 
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distributions of the measured covariates (See Supplementary eTable 1). Apart from previous 
hypoglycemia and a diagnosis of other CHD, the baseline characteristics of the weighted 
sample were not statistically different; as a result, the systematic differences between subjects 
in the treatment groups in the original cohort have been substantially reduced in the weighted 
sample (eTable 1). This shows that the differences between the treatment groups have been 
reduced by PS weighting and adequate balance on baseline covariates has been induced by 
the specification of the PS model used. 
Time to dual therapy failure 
The average time to treatment failure in the cohort of patients who added a 2nd line oral 
glucose lowering agent after MET is summarised in Table 2. Overall, 6,891 (44%) of patients 
who received a SU, 1,360 (44%) who received a DPP-4 inhibitor and 438 (30%) of patients 
who received TZD had to add or switch to another glucose lowering therapy during the study 
period. The mean time to treatment failure among TZD users was the longest at 3.3 years, 
followed by SU users (2.4 years) and then DPP-4 inhibitor (1.6 years). The unadjusted 
survival analysis showed the incidence of dual therapy failure at 1 year was 15% with SU, 
23% with DPP-4 inhibitor and 8% with TZD.  Corresponding failure rates at 2 years were 
26%, 38% and 12%, respectively (Figure 1). 
Estimating survival curves for treatment failure 
Crude Kaplan–Meier (KM) survival curves for subjects who added SU, DPP-4 inhibitor or 
TZD in the unadjusted original (unweighted) cohort are shown in Figure 1. The result shows 
there was a significant difference between the three curves; log-rank test p<0.001. The 
adjusted KM survival curves obtained from the PS weighted cohort were also significantly 
different (adjusted log-rank test p< 0.001) (See eFigure 2 in the supplement). From the 
estimated survival curves, our data showed that the rates of dual therapy failure were 
significantly different.  Second line use of a TZD was associated with the most durable 
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glycemic response, followed by the SU and then a DPP-4 inhibitor. The unadjusted survival 
analysis showed the incidence of dual therapy failure at 1 year was 15% with SU, 23% with 
DPP-4 inhibitor and 8% with TZD.  Corresponding failure rates at 2 years were 26%, 38% 
and 12% respectively (Figure 1). Thus, patients who added a DPP-4 inhibitor or SU to MET 
monotherapy were more likely to require a 3rd line glucose lowering agent than those who 
added a TZD.  
These results were consistent and remained significant in the adjusted multivariable Cox 
proportional hazards models, with DPP-4 inhibitor use (adjusted hazard ratio, aHR, 1.58; 
95%CI, 1.48-1.68) being associated with an increased hazard of dual therapy failure and TZD 
use (aHR, 0.45; 95%CI, 0.41-0.50) associated with a decreased hazard of treatment failure 
compared with SU, respectively (Table 2). 
In addition, factors predicting earlier failure of dual therapy on any of the glucose lowering 
agents were led by use of a lipid lowering drug, mainly statins (aHR = 1.57). Other 
significant risk factors included being female (aHR = 1.38), current smoking status (aHR = 
1.07), T2DM duration (aHR = 1.07), body weight (aHR = 1.02) and HbA1c (aHR = 1.02) 
(see eTable 21 in the supplement). 
Glycemic and body weight responses 
Results of the descriptive analysis showed that, overall, the co-administration of SU, DPP-4 
inhibitor and TZD to patients who had inadequate glycemic control with MET were 
associated with significant HbA1c reductions of -1.3%, -0.9% and -1.2%, respectively 
(p<0.001). Over the course of therapy, the addition of a SU produced between 0.3 and 0.5% 
greater reduction in HbA1c compared to the addition of a DPP-4 inhibitor whereas the 
addition of a TDZ appears to show a fluctuating pattern of reduction that was not 
significantly different from the SU (Figure 2).  In addition, the data show that addition of a 
2nd line oral agent to MET was associated with an overall 15% of patients meeting the HbA1c 
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target ≤6.5% and about 27% meeting the HbA1c target <7% after 1 year of dual therapy.  In 
terms of comparative responses at 1 year, the proportion of patients attaining HbA1c targets 
below 7% after using SU, DPP-4 inhibitor and TZD include 29%, 22% and 26%, respectively 
(Figure 4). resulted in similar proportions attaining HbA1c target of <7% had the best rate of 
HbA1c goal (HbA1c<7%) attainment (21%), followed by a DPP-4 inhibitor (5%) and then a 
TZD (1%) (Figure 4) 
In terms of overall changes in body weight, the addition of a TZD was associated with 
significant weight gain (1.8kg, p<0.001), while add-on DPP-4 inhibitor produced a 
significant weight reduction (-1.8kg, p<0.001). A very small reduction in body weight was 
observed with the SU (-0.2kg, p<0.001) (Figure 3). 
Sensitivity analyses  
We tested for violations of the proportional hazards assumptions using Schoenfeld residuals 
test, which tests the null hypothesis that the hazard ratio is constant over time. There is no 
evidence (P=0.5) to reject the assumption of proportional hazards for the treatment groups. 
The sensitivity analysis on missing data yielded comparable results to complete case models; 
the estimated aHR for DPP-4 inhibitor was 1.47 (95% CI: 1.34-1.60) and 0.50 for TZD (95% 
CI: 0.43-0.58), which reflects results that are unlikely to be attributable to bias from missing 
information. The probability density functions of the PS weighting of the treatment groups 
show there was no violation of the overlap assumption.21 (eFigure 3 in the supplement) 
 
Discussion 
This study has shown that in routine clinical practice, among patients with T2DM receiving a 
2nd line GLT as add-on to MET, the addition of a TZD is associated with the most durable 
glycemic response, followed by a SU and then a DPP-4 inhibitor. Factors associated with 
earlier dual therapy failure included concomitant use of statin therapy, being female, a 
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smoker, those with longer diabetes duration and higher baseline HbA1c levels. Adding an SU 
to MET as the 2nd line treatment gave the best chance of attaining an HbA1c goal of <7.5%. 
 
The Agency for Healthcare Research and Quality has suggested that the durability of 
glycemic response after treatment intensification is best investigated using well-designed 
long-term observational studies.22  Previous studies, however, have mainly focused on the 
durability of initial monotherapies, often in drug-naïve patients.5-7 The present study has 
focused on the most commonly prescribed add-on therapies to MET.  The results are similar 
to those in the ADOPT (A Diabetes Outcomes Progression) trial,7 which showed that ‘time to 
monotherapy failure’ was longer with rosiglitazone, a TZD no longer widely used, a TZD 
(rosiglitazone) compared with MET and a SU, glyburide.7 The ADOPT study which involved 
4,360 patients followed for a median of 4 years also reported rosiglitazone showed a 
significant greater reduction in HbA1c compared to SU (between-group absolute difference 
of -0.4%), which contrasts the HbA1c changes observed in our study. Combination therapies 
have been shown to have additive effects and are better at reducing HbA1c compared with 
monotherapy regimens. A recent review of 140 clinical trials and 26 observational studies on 
head-to-head comparisons of GLTs (MET, second-generation SU, TZD, meglitinides, DPP-4 
inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists) as monotherapy and 
combination therapy23 reported most medications decreased the HbA1c level by about 1% 
(absolute reduction).  A study conducted by the Quartet study group examined the long-term 
sustained effects of adding pioglitazone or gliclazide to failing MET monotherapy.24 The 2-
year, randomised, multicentre trial were performed in patients with inadequately controlled 
HbA1c (7.5-11% inclusive) and the mean reduction in HbA1c from baseline was 0.9% for 
TZD vs 0.8% for SU (p = 0.2). The SU group showed an initial better efficacy compared to 
TZD users, however, a progressive rise in HbA1c was observed by week 24 in both groups, 
with the SU group showing a more prominent increase. A similar initial pattern of reduction 
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was observed in our study. However, SU and TZD groups showed progressive increase after 
2 years of treatment.  
Observational studies have also shown that patients initially prescribed MET are significantly 
less likely to require treatment intensification than those who initiated treatment with other 
GLTs.5,6, 23 However, therapeutic responses to GLTs may be different when used as add-on to 
MET compared with monotherapy.25 The results of this real-world observational study are 
different to those of a previous randomized, controlled trial in which better durability of 
glycemic response was observed over 2 years with a DPP-4 inhibitor (sitagliptin) added to 
MET compared with a SU (glipizide).26 In addition, a recent real-world study by Inzucchi et 
al27 showed the opposite result to our study; patients treated with MET + sitagliptin showed a 
24% lower risk of insulin initiation over a 6-year period compared with MET + SU users (HR 
0.76; 95% CI 0.65–0.90). We speculate that one of the reasons for this disparity could be as a 
result of the different A1c levels characterised by the different cohorts. The study population 
examined by Inzuuchi et al had a mean A1c of approximately 8% compared to our study 
population with approximately 9% at baseline, moreover, the outcome of their stratification 
analysis which examined patients with A1c ≥9% was not statistically different between 
sitagliptin vs SU users, and results from their Cox model also showed that a 1% increase in 
A1c level was associated with a 20% increase in the risk of insulin initiation. The pattern of 
HbA1c reduction observed across the treatment groups over time was similar for SU and 
DPP-4 users, even though SU users maintained between -0.3% and -0.5% more reduction in 
HbA1c compared to DPP-4 inhibitor users. However, there was no consistent pattern seen 
with TZD users, which showed fluctuations in glycemic response after 48 weeks.  It appears 
the initial decline in HbA1c among TZD users was not as prominent as that seen with SU or 
DPP-4 inhibitor within the first 24 weeks of treatment. We assume the reason for this initial 
slow response could be explained by certain uncontrollable factors. For example, SU is an 
insulin secretagogue that acts to increase insulin secretion, whereas TZD acts by activating a 
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nuclear receptor thereby altering genetic transcription, however, TZDs also act without 
increasing insulin secretion. Therefore, the slow initial glycemic response observed with TZD 
is consistent with the response that should occur within the first 3 months of TZD 
administration.  
 
All 3 classes of GLTs assessed were associated with significant reductions in HbA1c. but The 
overall absolute 5-year mean change in HbA1c between SU, DPP-4 inhibitor and TZD was -
1.3%, -0.9% and -1.2%, respectively.  -1.2%, -0.8% and –0.9%, respectively at 2 years. The 
respective 2-year mean change obtained in our study (-1.2%, -0.8% and –0.9%) These results 
are consistent with previous evidence that an SU is superior to a TZD when added to MET,25 
while other studies have concluded that the efficacy of an SU is not superior to a DPP-4 
inhibitor28 or TZD23,28 when added to MET. In terms of goal attainment , most prospective 
randomized head-to-head trials of SU vs DPP-4 inhibitor co-administered with MET have 1 
to 2 years study duration and have similar proportions of patients who are lost to follow-up 
due to lack of efficacy. In terms of goal attainment, Similar proportions of patients attained 
glycemic efficacy (HbA1c < 7%) in our data; a higher proportion of patients on SU 
(29%28%) reached HbA1c <7% compared to those on DPP-4 inhibitor (22%) and TZD 
(26%) 6% vs 4%, respectively). Fewer patients treated with DPP-4 inhibitor and TZD 
reached this target at 1 year (5% vs 1%, respectively) as compared to SU (21%). In contrast, 
A similar result was obtained from a randomised active-comparator study, which showed the 
proportion of patients who achieved this target at 1 year was similar between SU and DPP-4 
inhibitors as add-on to MET (22.7% vs 23.1%, respectively).29 It is well known that the 
higher the HbA1c, the greater the reduction in HbA1c with all agents. Therefore, the higher 
HbA1c recorded for SU users at baseline (9.1%) compared to DPP-4 inhibitor vs TZD (8.6% 
vs 8.6%) may add more weight to the absolute mean change observed among SU users. 
Results obtained from RCTs and real-world data in the area of superiority between SU and 
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DPP-4inhibitor as the add-on therapies to MET vary, meaning that a definitive conclusion 
cannot be made on the superiority of either SU over DPP-4 inhibitor in controlling HbA1c in 
patients with T2DM. The results of this real-world data imply that future robust research 
should examine efficacy in subgroup of patients over time and what influences a clinician’s 
choice of treatment option. 
 
When used in combination with MET, weight loss was observed with DPP-4 inhibitor (-
1.8kg) vs. weight gain with TZD (1.8kg). The weight loss accompanying use of a DPP-4 
inhibitor appeared to be consistent 3 years from commencement of therapy. TZD-related 
weight gain was evident after 24 weeks and was progressive over 3 years. Placebo-controlled 
trials have shown TZD and SU increased body weight by 1 to 5kg.30 In a study of direct 
comparisons of monotherapies with TZD and SU, increased body weight was recorded with 
SU, even though this was lesser than that observed with TZD. Combinations of MET plus a 
TZD or MET plus SU increased weight more than MET monotherapy.23 In contrast, SU was 
associated with borderline weight loss in our study. The reason for this disparity cannot be 
explained from our data. However, we assume that underlying factors such as education, 
lifestyle changes and combination therapy with MET might have contributed to the weight 
loss observed. Moreover, the greater amount of weight gain induced by TZD compared with 
SU in our data is consistent with data from another RCT – the ADOPT study, where patients 
administered SU monotherapy gained weight during the first year of treatment and thereafter 
experienced a gradual decline in body weight during the subsequent years.7 On the other 
hand, the weight loss accompanying use of a DPP-4 inhibitor appeared to be consistent 3 
years from commencement of therapy. A previous study showed the co-administration of a 
DPP-4 inhibitor with MET is associated with similar weigh loss effect when compared with 
MET monotherapy, although the strength of evidence was low due to fewer studies on DPP-4 
inhibitors.23 In contrast, previous overviews have concluded there is no significant weight 
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change with a DPP-4 inhibitor (-0.14kg, 95%CI: -0.94 to 0.63kg), while SU and TZD were 
associated with 2.06kg vs 2.08kg weight gain, when used in combination with MET, 
respectively.28 Additional analysis conducted to investigate the correlation between change in 
body weight and change in HbA1c showed a significantly negative but weak association 
between change in HbA1c and change in weight in the cohort. (Pearson’s correlation 
coefficient, r = −0.03; p<0.001). Change in weight accounted for approximately 0.1% of the 
total variation in HbA1c change; for every 1kg increase in weight, HbA1c increased by an 
estimated 0.01%, which is clinically irrelevant. 
 
The risk for hypoglycemia with an SU has been reported to increase by 6-fold, compared 
with other GLT.23 Newer agents such as DPP-4 inhibitor when added to MET was also 
reported to reduce HbA1c levels, but without additional risk for hypoglycemia.23 
Unfortunately, we were not able to assess the incidence of hypoglycemia in our data due to 
inadequate reporting of hypo events. However, we were also able to identify other factors that 
may independently predict earlier need for treatment intensification. These include diabetes 
duration, gender, smoking status, body weight and the use of statins. These findings may be 
particularly relevant for evaluating whether the adherence to glucose lowering therapy could 
be influenced by individual patient characteristics and foster research on the characteristics of 
patients that benefit most from SU, DPP-4 inhibitors and other newer second line agents. Our 
observation that statin therapy is an independent predictor of an earlier need for treatment 
intensification is particularly interesting. The adverse metabolic effects of statins on insulin 
secretion and insulin sensitivity is being recognised.31  
 
Our analyses were subject to a number of limitations that are inherent to observational 
studies. Firstly, we cannot be certain that the patients were fully compliant with their 
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medication. However, any overestimation of exposure to the medications in our analysis such 
a misclassification would be non-differential and only bias results towards unity. Other 
factors apart from HbA1c may also influence the decision to intensify treatment in everyday 
practice. These may include unknown compliance, tolerability, safety, cost, physician’s 
reason for adding/substituting with a third oral agent and a patient’s preference. 
Unfortunately, but we were our analysis is unable to evaluate how these factors might have 
influenced the findings. These information are useful in the management of type 2 diabetes in 
routine clinical practice and can be best obtained through qualitative research studies. Other 
newer agents being added to MET monotherapy such as GLP-1receptor agonists and SGLT-2 
inhibitors were not assessed due to limited number of patients using them in our data. The 
failure to obtain similar data on SGLT-2 inhibitors and GLP-1receptor agonists is a major 
limitation of the present study. Although we could not account for potential residual 
confounders such as compliance, indications for intensification treatments, markers of β-cell 
deterioration and differences in dosages, we were able to account for differences in the 
observed covariates and used robust analytical techniques to control confounding that may 
bias the results of the estimated treatment effects. Our use of propensity score analysis to 
estimate average treatment effect in a large dataset contributed to the balancing of treatment 
and comparison groups on the available covariates without the loss of observations. However, 
the limitation to this technique is that it only accounts for observed covariates. Hence, other 
factors that may influence a physician’s choice of therapy that cannot be accounted for in the 
study or any other hidden biases that may remain after PS weighting l overlap between 
treatment and control groups. Furthermore, we ensured a thoughtful and thorough 
specification of the selection model was employed to successfully apply the propensity score 
weighting technique.  
 
18 
 
Conducting a randomized trial to compare the durability of different 2nd line GLTs would be 
challenging and there are none, to date, in the literature. In this study, we observed that in 
routine clinical practice, among patients with T2DM, the rates of dual therapy failure were 
significantly different between commonly used 2nd line oral GLTs. A TZD was associated 
with the most durable glycemic response at the expense of greater weight gain, followed by 
the SU and DPP-4 inhibitor. The study highlights important differences in glycemic 
outcomes among different 2nd line treatment options used in everyday practice. 
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Table 1: Characteristics of Patients at Treatment Intensification 
Baseline variable 
Total (N = 
20,070) 
MET + SU 
(n = 
15,508) 
MET + 
DPP-4i (n = 
3,080) 
MET + 
TZD (n = 
1,482) 
Effect 
Size a 
Effect 
Size b 
Demographics       
Age (yrs), Mean (SD) 59.2 (12.9) 59.8 (13.1) 57.2 (12.0) 56.8 (11.5) 0.23 0.07 
Gender, No. (%)       
Male 11741 (59) 9097 (59) 1767 (57) 877 (59) 0.04 0.02 
Female 8329 (41) 6411 (41) 1313 (43) 605 (41) 0.04 0.02 
Townsend deprivation, No. (%)       
Least deprived 4210 (21) 3140 (20) 751 (24) 319 (22) 0.10 0.03 
Less 3950 (20) 3036 (20) 625 (20) 289 (20) 0.02 0.01 
Average 4328 (22) 3388 (22) 644 (21) 296 (20) 0.05 0.04 
More 4297 (21) 3381 (22) 588 (19) 328 (22) 0.07 0.02 
Most deprived 3285 (16) 2563 (17) 472 (15) 250 (17) 0.04 0.02 
Clinical Parameters, Mean (SD)       
HbA1c (%) 9.0 (2.2) 9.1 (2.3) 8.6 (1.6) 8.6 (1.7) 0.24 0.07 
BMI (kg/m2) 31.7 (6.6) 31.1 (6.5) 33.8 (6.8) 33.3 (6.6) 0.41 0.05 
Weight (Kg) 90.9 (21.4) 89.0 (20.9) 97.8 (22.0) 96.0 (21.6) 0.41 0.06 
SBP (mmHg) 134.8 (15.6) 135.0 (15.9) 133.7 (14.6) 135.3 (14.4) 0.10 0.04 
DBP (mmHg) 79.4 (9.7) 79.4 (9.8) 79.6 (9.3) 79.8 (9.0) 0.05 0.01 
TC (mmol/l) 4.7 (1.3) 4.8 (1.4) 4.6 (1.2) 4.5 (1.2) 0.19 0.06 
HDL (mmol/l) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.05 0.02 
LDL (mmol/l) 2.6 (1.1) 2.7 (1.1) 2.5 (1.0) 2.5 (1.0) 0.20 0.05 
Triglyceride (mmol/L) 2.4 (2.5) 2.5 (2.7) 2.3 (1.9) 2.4 (2.5) 0.05 0.03 
GFR (mls/min/1.73m2) 73.8 (17.2) 73.4 (17.3) 75.7 (16.4) 74.7 (16.8) 0.13 0.02 
ACR (mg/mol) 4.1 (9.3) 4.3 (9.4) 3.9 (9.3) 3.2 (8.5) 0.12 0.05 
Diabetes duration (yrs) c 2.9 (3.6) 2.8 (3.6) 3.4 (3.3) 3.0 (3.2) 0.17 0.02 
Smoking status, No. (%)  
    
 
Non-smoker 8706 (43) 6787 (44) 1315 (43) 604 (41) 0.06 0.04 
Current smoker 3750 (19) 2935 (19) 534 (17) 281 (19) 0.04 0.01 
Ex-smoker 7614 (38) 5786 (37) 1231 (40) 597 (40) 0.06 0.03 
Use of Medications, No. (%)  
    
 
Aspirin 3803 (19) 2861 (18) 544 (18) 398 (27) 0.23 0.06 
Antihypertensive 10592 (53) 7985 (51) 1803 (59) 804 (54) 0.14 0.02 
LLT 11588 (58) 8506 (55) 2138 (69) 944 (64) 0.29 0.06 
Comorbidities, No. (%)  
    
 
Hypoglycemia 509 (3) 463 (3) 32 (1) 14 (1) 0.13 0.10 
CHD 270 (1) 230 (1) 21 (1) 19 (1) 0.07 0.06 
PAD 210 (1) 178 (1) 14 (0) 18 (1) 0.07 0.04 
Heart Failure 458 (2) 406 (3) 41 (1) 11 (1) 0.13 0.11 
Stroke 297 (1) 261 (2) 19 (1) 17 (1) 0.09 0.08 
       
Abbreviations: MET (metformin); SU (sulphonylurea); DPP-4 (dipeptidyl peptidase-4 inhibitor); INS (insulin); BMI (body 
mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (hemoglobin A1c); HDL (high-density 
lipoprotein); LDL (low-density lipoprotein); TC (total cholesterol); GFR (glomerular filtration rate); LLT (lipid lowering 
therapy); PAD (peripheral arterial disease); CHD (coronary heart disease); ACR (urinary albumin creatinine ratio); SD 
(standard deviation) 
 
Effect size (ES) is the absolute standardised mean difference of means or percentages divided by the standard deviation.  
a Unweighted ES 
 
b ES after propensity score weighted cohort  based on average treatment effect in the population (ATE). Differences between 
treatment groups have been reduced by weighting using the propensity score 
 
c Diabetes duration is time from first diagnosis of diabetes to date of intensification with 2nd line drug (index date) 
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Table 2: Rates, Hazard Ratios of Dual Therapy Failure and Glycemic and Weight Changes 
 MET + SU MET + DPP-4i MET + TZD  
Person-years 36,643 4,964 4,823 
Average time to treatment failure (yrs) 2.4 (1.7) 1.6 (1.3) 3.3 (1.7) 
    
Unadjusted failure rate (95% CI)    
Year 1 0.15 (0.14-0.16) 0.23 (0.22-0.25) 0.08 (0.07-0.10) 
Year 2 0.26 (0.25-0.27) 0.38 (0.37-0.41) 0.12 (0.10-0.14) 
Year 3 0.36 (0.35-0.37) 0.51 (0.48-0.53) 0.17 (0.15-0.19) 
Year 4 0.45 (0.44-0.46) 0.61 (0.59-0.64) 0.23 (0.21-0.26) 
Year 5 0.90 (0.88-0.91) - 0.64 (0.56-0.72) 
    
Adjusted hazard ratio (95% CI) a 1.0 [Reference] 1.58 (1.48-1.68) 0.45 (0.41-0.50) 
    
Mean (SD) HbA1c at endpoint (%) 7.8 (1.7) 7.7 (1.5) 7.3 (1.4) 
    
Mean (SD) HbA1c change, % b -1.3 (2.4) -0.9 (1.6) -1.2 (1.9) 
(mmol/mol) -14 (26) -10 (18) -13 (21) 
    
Year 1 -1.0 (2.0) -0.6 (1.4) -0.6 (1.7) 
 -11 (22) -7 (15) -7 (19) 
    
Year 2 -1.2 (2.3) -0.8 (1.6) -0.9 (1.9) 
 -13 (25) -9 (18) -10 (21) 
    
Mean (SD) Weight change, Kkg b -0.2 (6.7) -1.8 (6.3) +1.8 (8.8) 
    
Year 1 -0.4 (5.1) -0.7 (3.9) +0.2 (4.7) 
    
Year 2 -0.1 (5.8) -1.1 (4.8) +0.5 (6.1) 
    
Abbreviation: MET (metformin); SU (sulphonylurea); DPP-4i (dipeptidylpeptidase-4 inhibitor); TZD 
(thiazolidinedione); SD (standard deviation); HbA1c (glycated hemoglobin) 
a Adjusted for all baseline covariates and propensity score 
b Overall change in absolute value (values are running average) 
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Figure 1: Full cohort survival curves 
 
Figure 1 depicts the Kaplan-Meier survival curves for the treatment group (SU, DPP-4 inhibitor and TZD) 
participants in the original sample. The three survival curves are significantly different from one another (log-
rank test P value < 0.001) 
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Figure 2: Glycemic responses – HbA1c over time 
 
Figure 2 shows SU added to MET maintained a 0.3 to 0.5% greater reduction in HbA1c compared to MET plus 
DPP-4 inhibitor. There was no clear or consistent difference in HbA1c changes between SU and TZD when 
added to MET over time. (Note: Mean HbA1c changes are not running averages) 
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Figure 3: Body weight changes over time 
 
Figure 3 shows intensifying MET therapy with TZD was associated with weight gain over time, while DPP-4 inhibitor was 
associated with weight loss over time. SU was associated with neutral weight changes over time 
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Figure 1: Patients achieving HbA1c targets at 1 year 
 
Figure 4 shows HbA1c goal achievement was quite low for all dual therapies studied. The addition of SUs 
second line to MET had the best rate of HbA1c goal attainment, followed by DPP-4 inhibitors, and then TZDs 
